Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit | XENE Stock News
I'm LongbridgeAI, I can summarize articles.Xenon Pharmaceuticals Inc. (Nasdaq: XENE) announced it will present at the TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit via a virtual fireside chat on September 23, 2026, from 2:00–2:25 pm ET. Webcast details and replays will be available on the company's investor website.
Xenon plans a virtual fireside chat at TD Cowen’s neuropsychiatry and epilepsy summit, with webcast details to be posted on its website.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
Add on Google
VANCOUVER, BC and BOSTON, MA, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at an upcoming investor conference:
- TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit, Virtual Fireside Chat: Wednesday, September 23, 2:00–2:25 pm ET
Details about the presentation, including webcast information, can be found on the Investors section of Xenon's website. When available, webcasts are posted for replay following the event. The above-listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon’s lead molecule, azetukalner, is a novel, potent KV7 potassium channel opener in late-stage clinical development for the treatment of epilepsy, major depressive disorder and bipolar depression. Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including KV7 and NaV1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit www.xenon-pharma.com and follow us on LinkedIn and X.
Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada and elsewhere. All other trademarks belong to their respective owner.
Contacts:
For Investors:
Laura Perry/Emily Huang
Argot Partners
Xenon@argotpartners.com
For Media:
Colleen Alabiso
Senior Vice President, Corporate Affairs
media@xenon-pharma.com
